• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

上皮性卵巢癌干细胞的流行率与早期卵巢癌的复发相关。

Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.

机构信息

Department of Oncology, Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark.

出版信息

J Oncol. 2011;2011:620523. doi: 10.1155/2011/620523. Epub 2011 Aug 29.

DOI:10.1155/2011/620523
PMID:21904548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3166719/
Abstract

Epithelial ovarian cancer stem cells (EOC stem cells) have been associated with recurrence and chemoresistance. CD44 and CK18 are highly expressed in cancer stem cells and function as tools for their identification and characterization. We investigated the association between the number of CD44+ EOC stem cells in ovarian cancer tumors and progression-free survival. EOC stem cells exist as clusters located close to the stroma forming the cancer stem cell "niche". 17.1% of the samples reveled high number of CD44+ EOC stem cells (>20% positive cells). In addition, the number of CD44+ EOC stem cells was significantly higher in patients with early-stage ovarian cancer (FIGO I/II), and it was associated with shorter progression-free survival (P = 0.026). This study suggests that quantification of the number of EOC stem cells in the tumor can be used as a predictor of disease and could be applied for treatment selection in early-stage ovarian cancer.

摘要

上皮性卵巢癌干细胞（EOC 干细胞）与复发和化疗耐药有关。CD44 和 CK18 在癌症干细胞中高表达，并作为其鉴定和特征描述的工具。我们研究了卵巢癌肿瘤中 CD44+EOC 干细胞数量与无进展生存期之间的关系。EOC 干细胞作为位于靠近形成癌症干细胞“生态位”的基质的簇存在。17.1%的样本显示出高数量的 CD44+EOC 干细胞（>20%的阳性细胞）。此外，早期卵巢癌（FIGO I/II）患者的 CD44+EOC 干细胞数量明显更高，且与无进展生存期较短相关（P=0.026）。这项研究表明，肿瘤中 EOC 干细胞数量的定量可以作为疾病预测指标，并可应用于早期卵巢癌的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/26948d71e09d/JO2011-620523.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/4a83f77a911e/JO2011-620523.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/fb685683fa8c/JO2011-620523.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/fd90a5e2a7d0/JO2011-620523.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/675201891100/JO2011-620523.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/f69016d7812a/JO2011-620523.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/26948d71e09d/JO2011-620523.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/4a83f77a911e/JO2011-620523.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/fb685683fa8c/JO2011-620523.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/fd90a5e2a7d0/JO2011-620523.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/675201891100/JO2011-620523.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/f69016d7812a/JO2011-620523.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a07/3166719/26948d71e09d/JO2011-620523.006.jpg

相似文献

1
Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.上皮性卵巢癌干细胞的流行率与早期卵巢癌的复发相关。
J Oncol. 2011;2011:620523. doi: 10.1155/2011/620523. Epub 2011 Aug 29.
2
High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.高频率的具有 CD44/CK19 共表达的假定卵巢癌干细胞与复发性上皮性卵巢癌患者无进展间隔时间缩短相关。
Reprod Sci. 2013 May;20(5):605-15. doi: 10.1177/1933719112461183. Epub 2012 Nov 20.
3
Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.晚期浆液性上皮性卵巢癌中CD44表面表达的临床相关性：一项前瞻性研究。
J Cancer Res Clin Oncol. 2016 May;142(5):949-58. doi: 10.1007/s00432-016-2116-5. Epub 2016 Jan 13.
4
Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer.CD44/MyD88的共表达是晚期上皮性卵巢癌的一个不良预后因素。
Ann Transl Med. 2019 Mar;7(5):91. doi: 10.21037/atm.2019.01.28.
5
CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.CD44作为一种癌症干细胞标志物及其在卵巢癌患者中的预后价值。
J Obstet Gynaecol. 2018 Jan;38(1):110-114. doi: 10.1080/01443615.2017.1336753. Epub 2017 Aug 17.
6
NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.非甾体抗炎药激活基因1介导I型人上皮性卵巢癌干细胞样细胞中的促炎信号激活和紫杉醇化疗耐药性。
Oncotarget. 2016 Nov 1;7(44):72148-72166. doi: 10.18632/oncotarget.12355.
7
TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.TLR2 增强卵巢癌干细胞自我更新，促进肿瘤修复和复发。
Cell Cycle. 2013 Feb 1;12(3):511-21. doi: 10.4161/cc.23406. Epub 2013 Jan 16.
8
Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer.肿瘤-间质比在上皮性卵巢癌中的预后意义
Biomed Res Int. 2015;2015:589301. doi: 10.1155/2015/589301. Epub 2015 Nov 1.
9
Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.I型和II型上皮性卵巢癌的临床病理特征及HE4表现的差异
Int J Clin Exp Med. 2015 Nov 15;8(11):21303-10. eCollection 2015.
10
Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.高表达 ROR1 的卵巢癌干细胞可作为卵巢癌的新型预防性疫苗。
J Immunol Res. 2019 Mar 17;2019:9394615. doi: 10.1155/2019/9394615. eCollection 2019.

引用本文的文献

1
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib.转化生长因子β与上皮-间质转化改变同源重组修复基因表达并使BRCA野生型卵巢癌细胞对奥拉帕尼敏感。
Cancers (Basel). 2023 Aug 1;15(15):3919. doi: 10.3390/cancers15153919.
2
Identification of Prognosis Biomarkers for High-Grade Serous Ovarian Cancer Based on Stemness.基于干性的高级别浆液性卵巢癌预后生物标志物的鉴定
Front Genet. 2022 Mar 14;13:861954. doi: 10.3389/fgene.2022.861954. eCollection 2022.
3
Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies.

本文引用的文献

1
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.醛脱氢酶与 CD133 联合定义了血管生成性卵巢癌干细胞，预示着患者预后不良。
Cancer Res. 2011 Jun 1;71(11):3991-4001. doi: 10.1158/0008-5472.CAN-10-3175. Epub 2011 Apr 15.
2
Cancer stem cells and epithelial ovarian cancer.癌症干细胞与上皮性卵巢癌。
J Oncol. 2010;2010:105269. doi: 10.1155/2010/105269. Epub 2011 Jan 24.
3
Ovarian cancer stem cells and inflammation.卵巢癌干细胞与炎症。
卵巢癌中的癌症干细胞——肿瘤成功的根源和新型治疗的挑战性靶点。
Int J Mol Sci. 2022 Feb 24;23(5):2496. doi: 10.3390/ijms23052496.
4
Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer.单细胞衍生的球体捕获转移性卵巢癌的自我更新亚群。
Cell Death Differ. 2022 Mar;29(3):614-626. doi: 10.1038/s41418-021-00878-w. Epub 2021 Nov 29.
5
NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44.自然杀伤细胞通过一种针对CD44的新型嵌合抗原受体介导对卵巢癌细胞的清除。
Biomedicines. 2021 Sep 28;9(10):1339. doi: 10.3390/biomedicines9101339.
6
New Predictive Biomarkers for Ovarian Cancer.卵巢癌的新型预测生物标志物
Diagnostics (Basel). 2021 Mar 7;11(3):465. doi: 10.3390/diagnostics11030465.
7
A Marine Collagen-Based Biomimetic Hydrogel Recapitulates Cancer Stem Cell Niche and Enhances Progression and Chemoresistance in Human Ovarian Cancer.一种基于海洋胶原蛋白的仿生水凝胶模拟癌症干细胞微环境并增强人卵巢癌的进展和化疗耐药性。
Mar Drugs. 2020 Sep 29;18(10):498. doi: 10.3390/md18100498.
8
Leucine Zipper-EF-Hand Containing Transmembrane Protein 1 Is a Potential Prognostic Biomarker and Promotes Cell Progression in Prostate Cancer.含亮氨酸拉链-EF手型结构域的跨膜蛋白1是一种潜在的前列腺癌预后生物标志物并促进前列腺癌细胞进展
Cancer Manag Res. 2020 Mar 6;12:1649-1660. doi: 10.2147/CMAR.S236482. eCollection 2020.
9
The Role of Intra-Tumoral Heterogeneity and Its Clinical Relevance in Epithelial Ovarian Cancer Recurrence and Metastasis.肿瘤内异质性及其临床相关性在上皮性卵巢癌复发和转移中的作用
Cancers (Basel). 2019 Jul 30;11(8):1083. doi: 10.3390/cancers11081083.
10
Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.癌症干细胞富集和化疗耐药的工程 3D 模型。
Neoplasia. 2019 Aug;21(8):822-836. doi: 10.1016/j.neo.2019.06.005. Epub 2019 Jul 9.
Cancer Biol Ther. 2011 Apr 15;11(8):708-13. doi: 10.4161/cbt.11.8.14967.
4
Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.利用肿瘤干细胞假说靶向化疗和放疗抵抗的机制。
J Oncol. 2011;2011:941876. doi: 10.1155/2011/941876. Epub 2010 Oct 12.
5
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.人类上皮性癌中干细胞标志物醛脱氢酶 1 同工酶（ALDH1）的不同表达水平和模式。
PLoS One. 2010 Apr 21;5(4):e10277. doi: 10.1371/journal.pone.0010277.
6
TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214.通过 MIR199A2/214 扭转型卵巢癌细胞的干性、炎症和增殖。
Oncogene. 2010 Jun 17;29(24):3545-53. doi: 10.1038/onc.2010.111. Epub 2010 Apr 19.
7
Stem-like ovarian cancer cells can serve as tumor vascular progenitors.类干细胞卵巢癌细胞可作为肿瘤血管祖细胞。
Stem Cells. 2009 Oct;27(10):2405-13. doi: 10.1002/stem.191.
8
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
9
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.人卵巢癌干细胞的分子表型分析揭示了修复和化疗耐药机制。
Cell Cycle. 2009 Jan 1;8(1):158-66. doi: 10.4161/cc.8.1.7533.
10
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.浆液性输卵管上皮内癌：其在原发性腹膜浆液性癌及浆液性癌预防中的潜在作用
J Clin Oncol. 2008 Sep 1;26(25):4160-5. doi: 10.1200/JCO.2008.16.4814.